Have a website account?
Log In
or
Register
for exclusive website content.
Subscribe
Advanced Search
Home
Journal Info
About
cco
Indexing and Archiving
Editors-in-Chief
Editorial Board
Former Editorial Board
Peer Review Process
Supplements and Series
Advertising Policy
For Authors
Author Instruction
Online Submission
Submit Multimedia Files
Reference Style
AME Editing Service
Interviews with Outstanding Authors
For Reviewers
Guidelines for Reviewers
Online Review
Reviewers
Ethics and Policies
Journal Management (Editorial Roles)
Editorial Policies
Publication Ethics Policy
Research Ethics Policy
Human and Animal Rights
Authorship and Contributorship
Informed Consent Policy
Conflicts of Interest
Data Sharing Policy
Open Access Statement
Content Licensing
Copyright and Permission
Quality Control System
Data and Reproducibility
Policy of Screening for Plagiarism Process
Policy of Dealing with Allegations of Research Misconduct
Corrections and Retractions
Complaints and Appeals
Special Contents
Special Series (Published)
Special Series (Ongoing)
Interviews with Guest Editors
Interviews with Editorial Board Members
Archives
Online First
Article Processing Charges
News
Home
/
Archives
/
Vol 8, Supplement 1 (October 22, 2019): Chinese Clinical Oncology
Vol 8, Supplement 1 (October 22, 2019): Chinese Clinical Oncology
Editorial
Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets
Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
PDF
Pages: S1
Full Text
(1513)
Open Access
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
Francesco Facchinetti, Marcello Tiseo
PDF
Pages: S2
Full Text
(3252)
Open Access
Does bisphosphonate treatment reduce the risk of future cancer?
Michael Pazianas, Bo Abrahamsen
PDF
Pages: S3
Full Text
(1535)
Open Access
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Tianhong Li, Weijie Ma, Eddie C. Tian
PDF
Pages: S4
Full Text
(3277)
Open Access
Perineural invasion in oral cancer: challenges, controversies and clinical impact
Sabrina Daniela da Silva, Luiz Paulo Kowalski
PDF
Pages: S5
Full Text
(5988)
Open Access
Recent changes in the American Joint Commission Cancer staging of human papilloma virus related oropharyngeal cancer: validating the present and envisioning the future
Brett A. Miles
PDF
Pages: S6
Full Text
(847)
Open Access
The dawn of a universal language for an emerging malignancy
Junichi Shindoh
PDF
Pages: S7
Full Text
(885)
Open Access
The 8th Edition of the American Joint Committee on Cancer (AJCC8) Staging Manual: any improvement in the prognostication of oral tongue cancer?
Alhadi Almangush, Tuula Salo
PDF
Pages: S8
Full Text
(5621)
Open Access
Considering sarcoma staging systems and their implications to personalized care
Rick L. Haas, Michiel A. J. van de Sande
PDF
Pages: S9
Full Text
(1097)
Open Access
Occult breast cancer: the uncommon presentation of a common disease
Angela Toss, Luca Moscetti, Stefano Cascinu
PDF
Pages: S10
Full Text
(5495)
Open Access
Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview
Jennifer K. Plichta
PDF
Pages: S11
Full Text
(3971)
Open Access
Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?
William W. Tseng, Sandro Pasquali, James S. Hu, Lawrence R. Menendez, Alessandro Gronchi
PDF
Pages: S12
Full Text
(1465)
Open Access
Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer
Swaroop Revannasiddaiah, Ishu Gupta, Santhosh Kumar Devadas
PDF
Pages: S13
Full Text
(906)
Open Access
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Francesco Ricci, Christophe Le Tourneau
PDF
Pages: S14
Full Text
(1307)
Open Access
What can National Registry data tell us about occult breast cancer?
John Benjamin Wild, Steven Thrush, Raghavan Vidya
PDF
Pages: S15
Full Text
(1244)
Open Access
Impact of hypochloremia in resected colorectal cancer patients
Mai Tsutsui, Seiichiro Yamamoto
PDF
Pages: S16
Full Text
(1818)
Open Access
A step ahead on CTHRC1, and not just reinventing the wheel!
Siddharth Turkar, Anant Ramaswamy, Vikas Ostwal
PDF
Pages: S17
Full Text
(1479)
Open Access
Editorial Commentary
Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications
Luiz Paulo Kowalski, Hugo Fontan Köhler
PDF
Pages: S18
Full Text
(3578)
Open Access
AJCC 8
th
edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?
Daniel H. Ahn, Tanios Bekaii-Saab
PDF
Pages: S19
Full Text
(1614)
Open Access
Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe
Adam Garsa, Jennifer C. Ho, Chaosu Hu, Eric L. Chang
PDF
Pages: S20
Full Text
(1651)
Open Access
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Veronica Mollica, Vincenzo Di Nunno, Francesco Massari
PDF
Pages: S21
Full Text
(3176)
Open Access
Chemotherapy of pancreatic cancer in patients with poor performance
Dominik Schulz, Hana Algül
PDF
Pages: S22
Full Text
(1715)
Open Access
Perioperative safety in patients with resectable synchronous colorectal liver metastases
Lucas D. Lee, Y. Nancy You
PDF
Pages: S23
Full Text
(1194)
Open Access
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy
Shawn Kothari, Everett E. Vokes
PDF
Pages: S24
Full Text
(2563)
Open Access
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
Ibrahim Aldoss, Guido Marcucci
PDF
Pages: S25
Full Text
(2298)
Open Access
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti
PDF
Pages: S26
Full Text
(1087)
Open Access
Letter to the Editor
A closer look at the staging of soft tissue sarcomas in an era of personalized medicine
Aileen C. Johnson, Kenneth Cardona
PDF
Pages: S27
Full Text
(877)
Open Access
Obituary
In memory of Dr. Henry T. Lynch
Daniel G. Haller
PDF
Pages: S28
Full Text
(1041)
Open Access
Disclosure:
The supplement was published without any sponsorship or funding.